Holen Sie sich die Stockscreener-App
17.85
1.65%
0.29
Schlusskurs vom Vortag:
$17.56
Offen:
$17.64
24-Stunden-Volumen:
273.57K
Relative Volume:
0.19
Marktkapitalisierung:
$1.75B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.84M
KGV:
-37.98
EPS:
-0.47
Netto-Cashflow:
$-44.23M
1W Leistung:
-0.28%
1M Leistung:
+17.74%
6M Leistung:
+46.55%
1J Leistung:
+57.41%
1-Tages-Spanne:
$17.57
$17.99
1-Wochen-Bereich:
$17.19
$18.22
52-Wochen-Spanne:
$8.9055
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Firmenname
Ars Pharmaceuticals Inc
Sektor
Branche
Telefon
858-771-9307
Adresse
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Vergleichen Sie SPRY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
17.85 | 1.66B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.06 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.89 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.54 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
570.65 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
278.64 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-08-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Bestätigt | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | Raymond James | Outperform |
| 2024-03-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Eingeleitet | William Blair | Outperform |
| 2022-12-13 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High? - Yahoo Finance
What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing' - Yahoo Finance
ARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle Epinephrine (SPRY) - Seeking Alpha
(SPRY) Technical Data - news.stocktradersdaily.com
ARS Pharmaceuticals: 'Betting On The Come' (NASDAQ:SPRY) - Seeking Alpha
ARS Pharmaceuticals: Insider Liquidity vs. Institutional Buying – A Contrarian Opportunity? - AInvest
ARS Pharmaceuticals: Navigating Insider Sales Amid Growth Catalysts - AInvest
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) added to Russell 2000 Growth-Defensive Index - MarketScreener
ARS Pharmaceuticals (SPRY) Soars 4.48% on Earnings, Partnership - AInvest
High Growth Tech Stocks in US for June 2025 - simplywall.st
Learn to Evaluate (SPRY) using the Charts - news.stocktradersdaily.com
ARS Pharmaceuticals | 6/18/25 - ktnv.com
FDA Reviewing Oral Epinephrine Film for Possible Approval - Allergic Living
Asthma Market to Expand Significantly by 2034, States - openPR.com
Asthma Market to Expand Significantly by 2034, States DelveInsight Report | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentech - Barchart.com
ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy - MSN
Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier” - Insider Monkey
Jim Cramer Discussed These 16 Stocks Recently - Insider Monkey
ARS Pharmaceuticals Earns Relative Strength Rating Upgrade - Investor's Business Daily
Long Term Trading Analysis for (SPRY) - news.stocktradersdaily.com
Bank of America Corp DE Has $1.70 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals - WBFF
Ameriprise Financial Inc. Buys 36,928 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
BNP Paribas Financial Markets Purchases New Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ProShare Advisors LLC Buys 3,436 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $354,000 Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
Deutsche Bank AG Increases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
Neffy provides needle-free relief to those with allergic reactions - KOIN.com
ARS brings relief to your whole home - KOIN.com
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
ARS Pharmaceuticals Leadership Takes Stage at 3 Major Investment Conferences This June - Stock Titan
(SPRY) Trading Advice - news.stocktradersdaily.com
D. E. Shaw & Co. Inc. Decreases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals: neffy - WCIV
Exploring US High Growth Tech Stocks In May 2025 - simplywall.st
Brent Saunders Sells 120,000 Shares of ARS Pharmaceuticals Inc (SPRY) - GuruFocus
Expert Dr. Chase shares insights on Neffy for summer allergy season - KOKH
FY2025 EPS Estimates for SPRY Cut by Cantor Fitzgerald - Defense World
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by The Manufacturers Life Insurance Company - Defense World
Needle-Free Emergency Epinephrine Now Available for Pediatric Patients - Dermatology Advisor
Leerink Partnrs Has Bearish Outlook for SPRY Q2 Earnings - Defense World
William Blair Brokers Lower Earnings Estimates for SPRY - Defense World
ARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 10.8% – Still a Buy? - Defense World
Price T Rowe Associates Inc. MD Reduces Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2025 Earnings Call Transcript - MSN
ARS Pharmaceuticals targets 80% commercial coverage for neffy in 2025 while expanding pediatric reach - MSN
Ars Pharmaceuticals’ Neffy Launch Boosts Market Prospects - TipRanks
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates - MSN
What You Need To Know About The ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analyst Downgrade Today - Yahoo Finance
Analysts Have Just Cut Their ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Revenue Estimates By 15% - simplywall.st
Finanzdaten der Ars Pharmaceuticals Inc-Aktie (SPRY)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.43%
1.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):